The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
The pharmacogenetic test, which runs on a platform from British company Genedrive, will be tested in two neonatal intensive care units in Manchester and Liverpool.
With the participation of five cancer centers and clinics, Taproot is hoping to build a national, prospective data registry that is much needed but has been difficult to advance to date.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
